COVID-19 Resource Center

COVID-19 Resource Center

Source:

Lacy BE, et al. Poster Fr014. Presented at: Digestive Disease Week; May 21-24, 2021 (virtual meeting).

Disclosures: Lacy reports attending a yearly scientific advisory board meeting for Ironwood Pharmaceuticals, Salix Pharmaceuticals, Alicos, and Arena Pharmaceuticals.
May 25, 2021
1 min watch
Save

VIDEO: One-third of IBS-C patients surveyed report worsening of symptoms during COVID-19

Source:

Lacy BE, et al. Poster Fr014. Presented at: Digestive Disease Week; May 21-24, 2021 (virtual meeting).

Disclosures: Lacy reports attending a yearly scientific advisory board meeting for Ironwood Pharmaceuticals, Salix Pharmaceuticals, Alicos, and Arena Pharmaceuticals.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video exclusive, Brian E. Lacy, MD, from Mayo Clinic, Jacksonville, Florida, spoke about a survey of patients with IBS with constipation in the era of COVID-19.

“In the midst of this pandemic, we should really urge our patients to speak out to us, whether primary care provider or specialist,” Lacy said. “Use telemedicine, talk about opportunities, talk about agents and treatments that might be available to improve their symptoms.”

He said one-third of patients reported worsening of IBS-C symptoms during the COVID-19 pandemic. Although many experienced anxiety and depression, about 25% canceled appointments to see healthcare providers because they were scared to go out during the pandemic.